SEARCH:   Advanced

Blood, 15 January 2007, Vol. 109, No. 2, pp. 399-404. Prepublished online as a Blood First Edition Paper on September 26, 2006; DOI 10.1182/blood-2006-05-020735. This Article Full Text (PDF) All Versions of this Article: blood-2006-05-020735v1 109/2/399    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Byrd, J. C. Articles by Grever, M. R Search for Related Content PubMed PubMed Citation Articles by Byrd, J. C. Articles by Grever, M. R Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted May 1, 2006 Accepted August 22, 2006 Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia John C. Byrd*, Thomas S Lin, James T Dalton, Di Wu, Mitch A Phelps, Beth Fischer, Mollie Moran, Kristie A Blum, Brad Rovin, Michelle Brooker-McEldowney, Sarah Broering, Larry J Schaaf, Amy J Johnson, David M Lucas, Nyla A Heerema, Gerard Lozanski, Donn C Young, Jose-Ramon Suerez, A. Dimitrios Colevas, and Michael R Grever Division of Hematology-Oncology, Dept. of Internal Medicine, Ohio State University, Columbus, OH Division of Pharmaceutics, College of Pharmacy, Ohio State University, Columbus, OH Division of Nephrology, Dept. of Medicine, Ohio State University, Columbus, OH Dept. of Pathology, Ohio State University, Columbus, OH Biostatistical Core, Comprehensive Cancer Center, Ohio State University, Columbus, OH Sanofi Aventis Pharmaceuticals, Bridgewater, NJ Cancer Therapy & Evaluation Program, National Cancer Institute, Bethesda, MD * Corresponding author; email: john.byrd{at}osumc.edu. Despite promising pre-clinical studies with the cyclin-dependent kinase inhibitor flavopiridol in chronic lymphocytic leukemia (CLL) and other diseases, previous clinical trials with this agent have been disappointing. The discovery of differential protein binding of flavopiridol in human and bovine serum contributed to an effective pharmacokinetic derived schedule of administration of this agent. Based upon pharmacokinetic modeling using our in vitro results and data from a previous trial, we initiated a phase I study utilizing a 30 minute loading dose followed by four hour infusion administered weekly for four of six weeks in patients with refractory CLL. Forty-two patients were enrolled on three cohorts (cohort 1: 30 mg/m2 loading dose followed by 30 mg/m2 four-hour infusion; cohort 2: 40 mg/m2 loading dose followed by 40 mg/m2 four-hour infusion; and cohort 3: level 1 dose for treatments 1-4, then a 30 mg/m2 loading dose followed by 50 mg/m2 four-hour infusion). The dose limiting toxicity using this novel schedule was hyper-acute tumor lysis syndrome. Aggressive prophylaxis and exclusion of patients with leukocyte counts greater than 200 x 109/L have made this drug safe to administer at the cohort 3 dose. Of the 42 patients treated, nineteen (45%) achieved a partial response with a median response duration that exceeds 12 months. Responses were noted in patients with genetically high risk disease, including 5 of 12 (42%) with del(17p13.1) and 13 of 18 (72%) with del(11q22.3). Flavopiridol administered using this novel schedule has significant clinical activity in refractory CLL. Patients with bulky disease and high risk genetic features have achieved durable responses thereby justifying further study of flavopiridol in CLL and other diseases. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. Delgado, S. Pillai, N. Phillips, S. Brunet, G. Pratt, J. Briones, R. Lovell, R. Martino, J. Ewing, A. Sureda, et al. Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis Ann. Onc., December 1, 2009; 20(12): 2007 - 2012. [Abstract] [Full Text] [PDF] S. Stilgenbauer, T. Zenz, D. Winkler, A. Buhler, R. F. Schlenk, S. Groner, R. Busch, M. Hensel, U. Duhrsen, J. Finke, et al. Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group J. Clin. Oncol., August 20, 2009; 27(24): 3994 - 4001. [Abstract] [Full Text] [PDF] K. F. Byth, A. Thomas, G. Hughes, C. Forder, A. McGregor, C. Geh, S. Oakes, C. Green, M. Walker, N. Newcombe, et al. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts Mol. Cancer Ther., July 1, 2009; 8(7): 1856 - 1866. [Abstract] [Full Text] [PDF] D. M. Lucas, R. B. Edwards, G. Lozanski, D. A. West, J. D. Shin, M. A. Vargo, M. E. Davis, D. M. Rozewski, A. J. Johnson, B.-N. Su, et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo Blood, May 7, 2009; 113(19): 4656 - 4666. [Abstract] [Full Text] [PDF] R. Chen, W. G. Wierda, S. Chubb, R. E. Hawtin, J. A. Fox, M. J. Keating, V. Gandhi, and W. Plunkett Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia Blood, May 7, 2009; 113(19): 4637 - 4645. [Abstract] [Full Text] [PDF] M. A. Phelps, T. S. Lin, A. J. Johnson, E. Hurh, D. M. Rozewski, K. L. Farley, D. Wu, K. A. Blum, B. Fischer, S. M. Mitchell, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia Blood, March 19, 2009; 113(12): 2637 - 2645. [Abstract] [Full Text] [PDF] K. A. Foon, M. Boyiadzis, S. R. Land, S. Marks, A. Raptis, L. Pietragallo, D. Meisner, A. Laman, M. Sulecki, A. Butchko, et al. Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia J. Clin. Oncol., February 1, 2009; 27(4): 498 - 503. [Abstract] [Full Text] [PDF] M. S. Squires, R. E. Feltell, N. G. Wallis, E. J. Lewis, D.-M. Smith, D. M. Cross, J. F. Lyons, and N. T. Thompson Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines Mol. Cancer Ther., February 1, 2009; 8(2): 324 - 332. [Abstract] [Full Text] [PDF] F.-T. Liu, S. G. Agrawal, Z. Movasaghi, P. B. Wyatt, I. U. Rehman, J. G. Gribben, A. C. Newland, and L. Jia Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib Blood, November 1, 2008; 112(9): 3835 - 3846. [Abstract] [Full Text] [PDF] M. L. Sorror, B. E. Storer, B. M. Sandmaier, M. Maris, J. Shizuru, R. Maziarz, E. Agura, T. R. Chauncey, M. A. Pulsipher, P. A. McSweeney, et al. Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning J. Clin. Oncol., October 20, 2008; 26(30): 4912 - 4920. [Abstract] [Full Text] [PDF] L. Kujawski, P. Ouillette, H. Erba, C. Saddler, A. Jakubowiak, M. Kaminski, K. Shedden, and S. N. Malek Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia Blood, September 1, 2008; 112(5): 1993 - 2003. [Abstract] [Full Text] [PDF] I. N. Fleming, M. Hogben, S. Frame, S. J. McClue, and S. R. Green Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents Clin. Cancer Res., July 1, 2008; 14(13): 4326 - 4335. [Abstract] [Full Text] [PDF] L. A. Andritsos, A. J. Johnson, G. Lozanski, W. Blum, C. Kefauver, F. Awan, L. L. Smith, R. Lapalombella, S. E. May, C. A. Raymond, et al. Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia J. Clin. Oncol., May 20, 2008; 26(15): 2519 - 2525. [Abstract] [Full Text] [PDF] G. Ambrosini, S. L. Seelman, L.-X. Qin, and G. K. Schwartz The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates the Effects of Topoisomerase I Poisons by Suppressing Rad51 Expression in a p53-Dependent Manner Cancer Res., April 1, 2008; 68(7): 2312 - 2320. [Abstract] [Full Text] [PDF] S.-R. A. Hussain, D. M. Lucas, A. J. Johnson, T. S. Lin, A. P. Bakaletz, V. X. Dang, S. Viatchenko-Karpinski, A. S. Ruppert, J. C. Byrd, P. Kuppusamy, et al. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium Blood, March 15, 2008; 111(6): 3190 - 3199. [Abstract] [Full Text] [PDF] C. Sekine, T. Sugihara, S. Miyake, H. Hirai, M. Yoshida, N. Miyasaka, and H. Kohsaka Successful Treatment of Animal Models of Rheumatoid Arthritis with Small-Molecule Cyclin-Dependent Kinase Inhibitors J. Immunol., February 1, 2008; 180(3): 1954 - 1961. [Abstract] [Full Text] [PDF] M. E. Smith, V. Cimica, S. Chinni, K. Challagulla, S. Mani, and G. V. Kalpana Rhabdoid Tumor Growth is Inhibited by Flavopiridol Clin. Cancer Res., January 15, 2008; 14(2): 523 - 532. [Abstract] [Full Text] [PDF] A. W. Hauswirth and U. Jager Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia Haematologica, January 1, 2008; 93(1): 14 - 19. [Full Text] [PDF] S. O'Brien New Agents in the Treatment of CLL Hematology, January 1, 2008; 2008(1): 457 - 464. [Abstract] [Full Text] [PDF] W. G. Wierda Treatments for Patients with Chronic Lymphocytic Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 297 - 305. [Abstract] [Full Text] [PDF] O. Rixe and T. Fojo Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient? Clin. Cancer Res., December 15, 2007; 13(24): 7280 - 7287. [Abstract] [Full Text] [PDF] K. A. Blum, D. Young, S. Broering, M. S. Lucas, B. Fischer, T. S. Lin, M. R. Grever, and J. C. Byrd Computed Tomography Scans Do Not Improve the Predictive Power of 1996 National Cancer Institute Sponsored Working Group Chronic Lymphocytic Leukemia Response Criteria J. Clin. Oncol., December 10, 2007; 25(35): 5624 - 5629. [Abstract] [Full Text] [PDF] C. Mitchell, M. A. Park, G. Zhang, A. Yacoub, D. T. Curiel, P. B. Fisher, J. D. Roberts, S. Grant, and P. Dent Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells Mol. Cancer Ther., December 1, 2007; 6(12): 3101 - 3112. [Abstract] [Full Text] [PDF] L. A. Moutouh-de Parseval, L. Weiss, R. J. DeLap, R. D. Knight, and J. B. Zeldis Tumor Lysis Syndrome/Tumor Flare Reaction in Lenalidomide-Treated Chronic Lymphocytic Leukemia J. Clin. Oncol., November 1, 2007; 25(31): 5047 - 5047. [Full Text] [PDF] S. K. Manna, R. S. Aggarwal, G. Sethi, B. B. Aggarwal, and G. T. Ramesh Morin (3,5,7,2',4'-Pentahydroxyflavone) Abolishes Nuclear Factor-{kappa}B Activation Induced by Various Carcinogens and Inflammatory Stimuli, Leading to Suppression of Nuclear Factor-{kappa}B-Regulated Gene Expression and Up-regulation of Apoptosis Clin. Cancer Res., April 1, 2007; 13(7): 2290 - 2297. [Abstract] [Full Text] [PDF] M. R. Grever, D. M. Lucas, G. W. Dewald, D. S. Neuberg, J. C. Reed, S. Kitada, I. W. Flinn, M. S. Tallman, F. R. Appelbaum, R. A. Larson, et al. Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997 J. Clin. Oncol., March 1, 2007; 25(7): 799 - 804. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020